AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 6b
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 3.0mg on C1D8, 3.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 7
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 60.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 8a
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 3.0mg of CM336 on the first day of first cycle (C1D1), 15.0mg on C1D8, 75.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 8b
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 4.0mg on C1D8, 4.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_group 9
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Patients will take 4.0mg of CM336 on the first day of first cycle (C1D1), 20.0mg on C1D8, 90.0mg on C1D15 and subsequent treatment cycles until there is evidence of disease progression, unacceptable toxicity or other reasons for treatment discontinuation.
Study NCT05299424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336_RP2D
Description: CM336 will be administered subcutaneously (SC) once a week (QW). Individual subjects may continue study treatment until disease progression/relapse, unacceptable toxicity, withdrawal of consent, receipt of other anti-MM therapies, death, loss to follow-up, or the end of study.
Study NCT04719637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRDS-001 Renal Denervation Ultrasound System
Description: Renal Denervation Ultrasound System
Study NCT06254378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus lifting with allograft
Description: Participants will receive sinus lifting and allograft with immediate implant in premolar-molar area.
Study NCT06362629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence assistant decision-making system (AIADMS) App
Description: Participants will be assisted to use the Artificial Intelligence assistant decision-making system (AIADMS) app during the process of management of AD, and be followed-up at the scheduled time points including 2 weeks, 4 weeks, 8 weeks, 12 weeks, 6 months and 12 months after treatment, and the evaluation of five treating objectives including PP-NRS, EASI, SCORAD, POEM, and DLQI should be done on the day of follow-up.
Study NCT05462262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering control
Description: The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.
Study NCT06254378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lifting without graft
Description: Participants will receive sinus lifting with immediate implant in premolar-molar area without graft
Study NCT05462262 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity lipid-lowering control
Description: The initial recommended therapy is 10-20mg atorvastatin, and the type and dosage of drugs can be adjusted according to the situation.
Study NCT05382286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously
Study NCT05382286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously
Study NCT06016244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation threshold
Description: Oxygen saturation threshold on which supplemental oxygen is decided
Study NCT06016244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen saturation threshold
Description: Oxygen saturation threshold on which supplemental oxygen is decided
Study NCT04450550 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeNS device
Description: VeNS treatment
Study NCT04450550 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VeNS device
Description: Sham treatment of VeNS
Study NCT06531018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag 25 MG
Description: Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Study NCT06531018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Study NCT06531018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 1-2 mg/kg and Placebo(same as eltrombopag 25mg Tablet), selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Study NCT05677347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be administered
Study NCT05382286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-Paclitaxel
Description: Administered intravenously
Study NCT05677347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered
Study NCT06127303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after cryoablation, until occurrence of termination event specified in the protocol.
Study NCT06127303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: The ablation was performed on the first day of each cycle, and the target lesions were comprehensively screened for cryoablation based on the location and size of the lesions.
Study NCT06063876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of experimental peri-implant mucositis
Description: Patients will refrain from oral hygiene measures at the implant sites for 3 weeks to induce peri-implant mucositis, by using a stent in the included implant during oral hygiene.
Study NCT06063876 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resolution of experimental peri-implant mucositis
Description: Patients will reinstitute oral hygiene measures, receive an oral prophylaxis and oral hygiene instructions and will be evaluated during 3 weeks.
Study NCT06106568 — intervention group
Intervention type: PROCEDURE
Intervention: EOB-MRI
Description: Retrospective analysis for pancreatic cancer patients who had a record of EOB-MRI in the Medical Data Vision (MDV) database in Japan
Study NCT06106568 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Retrospective analysis for pancreatic cancer patients who had a record of any surgery for the pancreatic cancer in the Medical Data Vision (MDV) database in Japan
Study NCT06106568 — intervention group
Intervention type: PROCEDURE
Intervention: Open-close Laparotomy
Description: Retrospective analysis for pancreatic cancer patients who had a record of an open-close laparotomy in the Medical Data Vision (MDV) database in Japan
Study NCT06549647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low caloric diet
Description: A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.
Study NCT06549647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low caloric diet
Description: A low caloric diet of 1200 Kcal will be followed by participant for 3 months. The dietary intervention follows a macronutrient ratio of 15% protein, 30% fat, and 55% carbohydrates. Participants are advised to consume 170-240g of complex carbohydrates, 60-100g of fat, and 55-93g of protein per day, with 20-35g of fiber. Patients are also advised to limit salt, tea, and caffeine intake, and receive supplemental vitamins to prevent deficiencies.
Study NCT06549647 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo laser acupoint stimulation
Description: Placebo laser acupoint stimulation will be used for all participants in group (A).
Study NCT06549647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: Eazyone EZ1 level laser will be used for the treatment procedures for all participants in group (B) only. Every participant in group (B) will be instructed briefly about the effect of laser acupoints therapy to gain her confidence and co-operation. It will be applied with infrared laser with 830 nm wavelength, 5 W power output and 0.5 J energy on the following acupoints while the patient lie in supine lying position. The head of the machine will be applied perpendicularly on each point for 1 min (17 min total), 3 times/ week for 4 weeks.
Study NCT05382286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered intravenously
Study NCT05382286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously
Study NCT06298396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Program using default MAP
Description: Each MAP uses a specific combination of stimulation parameters and electrode mode.
Study NCT06298396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Program using low-power 1 (LP1) MAP
Description: Each MAP uses a specific combination of stimulation parameters and electrode mode.
Study NCT06298396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Program using low-power 2 (LP2) MAP
Description: Each MAP uses a specific combination of stimulation parameters and electrode mode.
Study NCT06298396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Program using low-power 3 (LP3) MAP
Description: Each MAP uses a specific combination of stimulation parameters and electrode mode.
Study NCT06512363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
Study NCT06512363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ramelteon placebo
Description: Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
Study NCT06316570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early Dual Antiplatelet Therapy
Description: Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Ticagrelor (180mg) + Aspirin (100mg), one dose;~Days 2-7: Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day).
Study NCT06316570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1(within 6.0 hours of onset, before or after intravenous thrombolysis) : Placebo of Ticagrelor (180mg) + Placebo of Aspirin (100mg), one dose;~Days 2-7: Placebo of Ticagrelor (90mg/time, twice/day) + open-label Aspirin (100mg/time, once/day) ;~Days 8-90: open-label Aspirin (100mg/time, once/day).
Study NCT05064618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Am80
Description: medicine taken internally
Study NCT05064618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered intravenously at a dose of 1000mg/m2
Study NCT05064618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Administered intravenously at a dose of 125mg/m2
Study NCT05003700 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin and raltitrexed via the tumor feeding arteries every 3 weeks.
Study NCT05003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg once daily (QD) oral dosing.
Study NCT05003700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg intravenously every 3 weeks.
Study NCT06637059 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: observation alone
Study NCT06638918 — intervention group
Intervention type: DEVICE
Intervention: Virtual Reality
Description: The virtual reality (VR) intervention administers graded motor imagery (GMI) treatment for phantom limb pain. It consists of three stages: left right sorting task (a sorting task where participants sort images of left and right feet), explicit motor imagery (a series of guided imagery exercises administered via audio to facilitate focus on the phantom limb), and the limb simulation task (where participants perform a series of exercises with virtual legs to create the illusion of movement in their phantom limb). The limb simulation stage can also be conducted with leg trackers to generate a higher degree of illusion in the virtual legs.
Study NCT04030052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuwiq (low dose protocol)
Description: After receiving HEMLIBRA® for 1-6 months, rFVIII (NUWIQ®) will be given at low dose (25 ±5 units/kg/dose) every 7-14 days as part of a low dose factor exposure program and for on demand use for acute bleeding episodes/procedures. NUWIQ® will be administered intravenously (IV) via peripheral infusion. If the infant has a central line such as a PICC line or mediport this can be used.
Study NCT04030052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEMLIBRA
Description: Four weekly subcutaneous (SQ) injections of HEMLIBRA® loading doses of 3 mg/kg will be given. A total of 12 mg/kg within the first month is allowed for the loading doses. Maintenance dosing will follow, and will either be 1.5 mg/kg/dose weekly, 3 mg/kg/dose biweekly (every 2 weeks), or 6 mg/kg/dose every 4 weeks depending on the recommended dosing.
Study NCT06275958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doublet Chemotherapy, Standard Dose (100%)
Description: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
Study NCT06275958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doublet Chemotherapy, Dose-reduced (75%)
Description: 75% of: Capecitabine 1000mg / m2 oral at day 1-14 (every 3 weeks) Oxaliplatin 130mg/m2 at day 1 (every 3 weeks) OR 5-FU 400mg/m2 IV bolus at day 1 followed by 2400mg/m2 in 46 hours (every 2 weeks) Leucovorin 400mg/m2 day 1 (every 2 weeks) Oxaliplatin 85mg/m2 day 1 (every 2 weeks)
Study NCT06275958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy, Standard Dose (100%)
Description: - Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
Study NCT06275958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monotherapy, Dose-reduced (75%)
Description: 75% of:~- Capecitabine 1000mg/m2 oral at day 1-14 (every 3 weeks)
Study NCT06187714 — intervention group
Intervention type: PROCEDURE
Intervention: caudal block rate
Description: optic nerve sheath diameter measurement according to caudal block rate
Study NCT05822245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Low Dose
Description: PER-001 Low Dose Intravitreal Implant
Study NCT05822245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - High Dose
Description: PER-001 High Dose Intravitreal Implant
Study NCT05822245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PER-001 Intravitreal Implant - Sham
Description: PER-001 Intravitreal Sham
Study NCT04030052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuwiq (Atlanta protocol)
Description: After completing HEMLIBRA® loading doses, participants will receive intravenous (IV) infusions of NUWIQ® 3 times per week, 100 units/kg the Atlanta protocol. Infusions will be given at least 36 hours from the previous NUWIQ® injection. Participants will continue on the HEMLIBRA® SQ - NUWIQ® IV treatment regimen for up to 12 months of NUWIQ® treatment.
Study NCT05023018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEO100
Description: NEO100 is a purified form of perillyl alcohol.
Study NCT00627549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Avaulta (surgical procedure using a mesh implant)
Description: The use of Avaulta
Study NCT00627549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional surgery (anterior repair)
Description: Anterior repair surgery
Study NCT05891860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participation in virtual rounds
Description: Virtual participation in daily ICU team rounds
Study NCT05475925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-01
Description: DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.
Study NCT06159608 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)
Description: Differences in endothelium- and nitric oxide (NO)-dependent dilation between groups
Study NCT06159608 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chronic estrogen exposure
Description: differences in urine estrogen levels across the menstrual cycle between women groups only
Study NCT05590195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preforpro
Description: Preforpro will be investigated to improve vaginal health in women with BV.
Study NCT05590195 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules manufactured to look like Preforpro capsules
Study NCT06570720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-focused Support of Survivors in Sororities Training (ASSIST)
Description: A web-based intervention that includes sorority and individual values, personalized normative feedback (adapted to address sexual assault, support, and acceptability of encouraging peer drinking), psychoeducation on sexual assault and alcohol, and skills training in behaviors to support sexual assault survivors without heavy drinking.
Study NCT06334029 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional and structural Connectome
Description: Reconstruction of EEG derived functional relationship between brain regions (functional connectome). Reconstruction of thickness covariance across brain regions (structural connectome)
Study NCT06167746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Health Information (DHI)
Description: Digital health information websites.
Study NCT06167746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Health Information (DHI)
Description: Digital health information websites.
Study NCT06167746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Health Coach for You
Description: Study participants in the intervention group will receive 10-session virtual health coaching intervention session delivered over 6 months with the goal of improving caregiver self-care and coping, decreasing stress, and improving the hospital-to-home experience The 10 sessions are on average 60 minutes and cover the following topics: care transitions, caregiving demand, self-care, and coping.
Study NCT04932759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music listening
Description: music listening during dental treatment
Study NCT06203574 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-T4 or [18F]AlF-RESCA-T4
Description: The dose of \[68Ga\]Ga-NOTA-T4 or \[18F\]AlF-RESCA-T4 was calculated based on the patient's body weight to be 3.7 MBq \[0.1 mCi\]/kg, and the method of administration was intravenous push, with one single imaging administration.
Study NCT05818423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Academy
Description: The Brain Health Academy group will review online content about brain health (1 hour, 2 days/week for 12 weeks) and will complete a brief survey after each module to assess compliance (30 hours total).
Study NCT05818423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Together
Description: The Brain Health Together group will participate in online, live-streaming, group-based Moving Together classes (1 hour/week); Brain Health education group classes (1 hour/week) and individual brain health coaching sessions (0.5 hours/week) for 12 weeks (30 hours total).
Study NCT05818423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintain Brain Health Together
Description: The Maintaining Brain Health Together group will participate in the full Brain Health Together program (30 hours) for 12 weeks followed by weekly group classes and six individual coaching for an additional 12 weeks (additional 15 hours).